Business Wire

emporia: Smartphones Now More Popular Than Landline Phones Among the Over 60s

4.9.2019 10:00:00 EEST | Business Wire | Press release

Share

Three out of four senior citizens would rather live without a conventional landline telephone than their smartphone. These are the findings of the 2019 Senior Citizens Survey: Smart Technology - Everyday, conducted by emporia Telecom in partnership with the German Senior Citizens League, in which 500 smartphone owners aged over 60 were interviewed.

Digital communication has become a simple matter of fact for many older people . One significant reason according to 83 percent of interviewees is: it is easier to maintain contact with family and friends via a smartphone.

According to the survey, three-quarters of senior citizens don’t want to be without their smartphone when they are out and about. It's also essential to them when travelling. It means that they always have useful information to hand, like weather forecasts and maps.

But it's far from every senior citizen that enjoys the benefits of the digital world. “75 million senior citizens in the EU today still don't own a smartphone. Yet there is an ever-increasing number of day-to-day activities that can only be performed with one. It's important to keep up to pace with modern communication technology so that you don’t suddenly find yourself cut adrift,” says Eveline Pupeter, owner and CEO of emporia Telecom. “It's our mission to guide older people into the digital future.”

The survey clearly identifies the concerns and difficulties experienced by senior citizens. Many older people worry about being left behind in a technology-driven world. For example, they wonder if they will even be able to perform daily errands and tasks such as using banking services, dealing with public authorities or buying bus and train tickets just as easily as they could before. “There's no stopping the progress of technology, but technology can also be simplified,” says emporia boss Eveline Pupeter. “We are seeking to gradually break down the fear of interacting with technology, and to help get the older generation up and ready for the future with user-friendly smartphones.

emporia is presenting two innovations simultaneously this September: The emporiaSMART.3 and the emporiaSMART.3mini. Despite their simplicity of use, both smartphones are fully intelligent, highly complex and state-of-the-art devices.

The emporiaSMART.3 is an easy-to-use top-class smartphone equipped with all the usual features such as two cameras, a powerful battery, Wi-Fi, Bluetooth, GPS, 5.5” screen, Type-C charging etc. It has a simple interface and mechanical home button and it’s also dust and splash-proof, compatible with hearing aids, has a sound amplifier, emergency call button, charging station and learning manual.

The SMART.3mini is something special. It was developed specially for men who wanted a compact smartphone that would easily fit into their trouser or shirt pocket. The SMART.3mini features a 4.95 inch touchscreen, meaning it's still easy to see and use. Spec-wise he mini is every bit the equal of its big brother, the SMART.

Talking about her mission, Eveline Pupeter says: “75 million of 65+ senior citizens in the EU still don't have a smartphone. It's emporia's goal to guide this generation into the digital future. Because being “smart” has nothing to do with age.”

The Linz-based manufacturer has a dual approach towards bringing digitalisation to the older generation. Its hardware and software solutions are precisely tailored for this target group. But it has also developed new training courses (such as Smartphones for Beginners, WhatsApp courses, Staying Secure on the Smartphone) to make it easier for senior citizens to get started.

emporia, the technology leader

emporia is an Austrian company that develops, manufactures and markets mobile telephones, smartphones and apps for the older generation. emporia’s products also include a wide range of accessories and landline telephones. Founded in 1991, emporia now operates in more than 30 countries around the world. The company is wholly owned by Eveline Pupeter who runs the business, together with her experienced management team. emporia employs 100 people. Its head office is located in the city of Linz on the banks of the Danube.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Walter Deil
+43 670 7010 322
deil@emporia.at

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye